Natalie Barnett, PhD

Barnett, N.L. DNA fingerprinting for routine pedigree recording. Chapter in Animal Breeding- Use of New Technologies (1999, edited by Kinghorn, B and van der Werf, J.) Post Graduate Foundation in Veterinary Science, Sydney Australia.

-

Barnett, N.L., Lindsay, D.R. and Lewer, R.P. Staple strength can be indirectly selected for by the use of genetically correlated visually assessed traits. Aust. Assoc. Anim. Prod. 21:480.

-

Barnett, N.L., Purvis, I.W., Stewart, V.A.M. and Franklin, I.R. At what price is DNA pedigreeing cost effective for Merino breeders? Proc. Assoc. Advmt. Anim. Breed. Genet. 12:425-8.

-

Barnett, N.L., Purvis, I.W., van Hest, B. and Franklin, I.R. The accuracy of current dam pedigree recording strategies employed by stud Merino breeders. Proc. Assoc. Advmt. Anim. Breed. Genet. 13:373-6.

-

Barnett, N.L., Swan, A.A. and Purvis, I.W. Benefit-cost analyses of recording dam pedigrees in Merino sheep improvement programs. 6WCGALP 24: 19-22.

-

Barnett, N.L., Swan, A.A. and Purvis, I.W. Benefit-cost analyses of recording dam pedigrees in Merino sheep improvement programs. Wool Tech. and Sheep Breed. 46(2):119-23.

-

Kolodny, EH, Neudorfer, O, Gianutsos, J, Zaroff, C, Barnett, N, Zeng, B, Raghavan, S, Torres, P, Pastores, G. Late-onset Tay-Sachs disease: natural history and treatment with OGT 918 (Zavesca (TM)). J. Neurochem. July 2004

-

Mankin HJ, Trahan CA, Barnett N.L., Laughead J, Bove CM, Pastores GM. A questionnaire study for 128 patients with Gaucher disease. Clin Genet. (2006) Mar;69(3):209-17.

-

Natalie Barnett, Assaf Glazer, Tor Ivry, Yanai Ankri, Haviva Veler. Computer vision algorithms outperform actigraphy. ERJ Open Research 5 (suppl 3) P134.

Pastores GM, Barnett NL, Kolodny EH. An open-label, non- comparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin. Ther. (2005) 27:1215-27.

-

Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N. Nephrol Dial Transplant. (2007) Jul;22(7):1920-5. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.

-

Pastores, G.M. and Barnett, N.L. Current and emerging therapies for the lysosomal storage disorders. Expert Opin. Emerging Drugs (2005)10(4):891-902.

-

Pastores, G.M. and Barnett, N.L. Substrate Reduction therapy: Miglustat as a remedy for symptomatic patients with Gaucher Disease type 1. Expert Opin. Investig. Drugs (2003) 12(2): 273-81. Barnett, N.L. DNA fingerprinting for routine pedigree recording.

-

Pastores, G.M., Barnett, N.L., Bathan, P. and Kolodny, E.H. A Neurological Symptom Survey of Patients with Type 1 Gaucher disease. J. Inherit. Metab. Dis. (2003) 26: 641-645.

-

Pastores, Gregory & Charria, GA & Barnett, N & Hilz, M & Kolodny, EH. Autonomic failure with a fatal outcome in Fabry disease. Acta Paediatrica - ACTA PAEDIAT. (2007) 91. 144-144.

-